Frontiers SARS-CoV-2 Spike Protein Expression In Vitro and

Severe COVID-19 can be associated with a prothrombotic state, increasing risk of morbidity and mortality. The SARS-CoV-2 spike glycoprotein is purported to d

Frontiers Display of receptor-binding domain of SARS-CoV-2 Spike protein variants on the Saccharomyces cerevisiae cell surface

Frontiers Stabilization of the SARS-CoV-2 Spike Receptor-Binding Domain Using Deep Mutational Scanning and Structure-Based Design

Frontiers Understanding the Role of SARS-CoV-2 ORF3a in Viral Pathogenesis and COVID-19

Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities

Frontiers SARS-CoV-2 Within-Host and in vitro Genomic Variability and Sub-Genomic RNA Levels Indicate Differences in Viral Expression Between Clinical Cohorts and in vitro Culture

Frontiers Nucleic Acid-Based Treatments Against COVID-19

Frontiers Variant-dependent oxidative and cytokine responses of human neutrophils to SARS-CoV-2 spike protein and anti-spike IgG1 antibodies

Aptamer-Mediated Antiviral Approaches for SARS-CoV-2

Full article: An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen

Frontiers SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development